Month: September 2020

MONTRÉAL, 17 sept. 2020 (GLOBE NEWSWIRE) — Kintavar Exploration Inc. (la «Société» ou «Kintavar») (TSX-V: KTR) (FRANCFORT: 58V), est très heureuse d’annoncer que son partenaire IAMGOLD Corporation («IAMGOLD») a débuté les travaux d’exploration sur le projet aurifère Anik dans la région de Chibougamau au Québec. Les travaux sur le terrain consisteront en levés supplémentaires de till et en révision et caractérisation des forages, des affleurements et des tranchées qui ont été réalisés ou mis à jour par Kintavar sur la propriété. La compilation des données géophysiques et géochimiques des divers levés se poursuit et permettra à l’équipe d’exploration d’identifier et de planifier les cibles de forages dont la réalisation est prévue à l’hiver prochain.«L’équipe technique d’IAMGOLD est composée de professionnels...

Thomas Taapken, Ph.D. appointed Chief Financial OfficerJordan Zwick promoted to Chief Strategy OfficerJENA, Germany, Sept. 17, 2020 (GLOBE NEWSWIRE) — InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today announced two management appointments. Effective October 1, 2020, Thomas Taapken, Ph.D. will join InflaRx as Chief Financial Officer. Jordan Zwick has been promoted to Chief Strategy Officer, effective immediately.Prof. Niels C. Riedemann, Chief Executive Officer and Founder of InflaRx, said: “I am delighted to welcome Thomas to InflaRx. He brings extensive senior management expertise in the public biopharmaceutical sector, including at companies with marketed products, and is an ideal fit as we advance our late-stage clinical development...

VANCOUVER, Sept. 17, 2020 (GLOBE NEWSWIRE) — BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAT) an emerging biotech company, today announced it has entered into an agreement with List Biological Laboratories, Inc. (“List Labs”) for the manufacture of its proprietary interferon alpha 2b for the treatment of COVID-19.“Following our recent merger, we are proud to be continuing the development of Altum Pharmaceutical’s proprietary interferon alpha 2b inhalation for treatment of COVID-19. We look forward to working with List Labs to bring this treatment to patients as quickly as possible as we prepare for our imminent trials in Australia” said BetterLife’s Chief Executive Officer, Dr. Ahmad Doroudian.Under the terms of the agreement, List Labs will provide manufacturing services...

COLUMBIA, Md., Sept. 17, 2020 (GLOBE NEWSWIRE) — Rekor Systems, Inc. (NASDAQ:REKR) (“Rekor”) (“the Company”), a Maryland-based company providing real-time roadway intelligence through AI-driven decisions, announced today that the company is now substantially debt free following the retirement of approximately $4.9 million in debt. The debt retirement eliminates all remaining short and long-term liability for Notes on the Company’s balance sheet, including accreted interest and all fees payable upon retirement of the Notes. In addition, Matt Hill, Rekor’s Chief Science Officer, exercised 625,000 warrants stemming from the purchase of OpenALPR in March 2019. “Becoming essentially debt free is a significant milestone for Rekor. It immediately transforms the balance sheet and increases available cashflow. This will enable...

CALGARY, Alberta, Sept. 17, 2020 (GLOBE NEWSWIRE) — Athabasca Minerals Inc. (“Athabasca” or the “Corporation”) (TSXV:AMI) announces the signing of a Term Sheet by its subsidiary, AMI Silica Inc., with an international industrial partner (“Industrial Partner”) to pursue the Duvernay Silica Sand Project as a joint venture (“JV”) initiative. This JV initiative aims to co-develop and operate one of the greenest silica sand facilities in North America. The facility would be located in Northeastern Alberta, offering unique synergies such as:industrial land suitable for construction;access to industrial utilities, including process water, power and heat recovery opportunities that bring distinctive environmental benefits;access to transportation infrastructure that will broaden the economic distribution of product across Alberta and into...

SOUTH SAN FRANCISCO, Calif., Sept. 17, 2020 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that GALACTIC-HF (Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility in Heart Failure), the Phase 3 pivotal cardiovascular outcomes trial of omecamtiv mecarbil in patients with heart failure with reduced ejection fraction (HFrEF), has been accepted for presentation in a virtual Late Breaking Clinical Trial session at the American Heart Association (AHA) Scientific Sessions 2020 on Friday, November 13, 2020.In anticipation of potentially having results available for presentation at the AHA Scientific Sessions 2020, an abstract relating to the design of GALACTIC-HF was submitted. The trial is proceeding toward conclusion, including planned database lock and data analyses. Topline...

NEW YORK, Sept. 17, 2020 (GLOBE NEWSWIRE) — Acreage Holdings, Inc. (“Acreage” or the “Company”) (CSE: ACRG.U) (OTCQX: ACRGF) (FSE: 0VZ) a vertically integrated, multi-state operator of cannabis licenses and assets in the U.S., today announced it will participate in two upcoming virtual investor conferences in September 2020. Alliance Global Partners’ Virtual Consumer Cannabis Conference 2020: On September 29th, Acreage director and former Speaker of the House, John Boehner will give the keynote address at the Alliance Global Partners’ Virtual Consumer Cannabis Conference 2020.  Interim Chief Executive Officer William Van Faasen and Chief Financial Officer Glen Leibowitz will also participate in and host investor meetings at the conference.Canaccord 2020 Virtual U.S. Cannabis Symposium:  On September 30th, Chief Financial Officer...

DENVER, Sept. 17, 2020 (GLOBE NEWSWIRE) — Mydecine Innovations Group, Inc. (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), is pleased to announce that its wholly-owned subsidiary, Mindleap Health (“Mindleap”), has implemented a comprehensive information security rollout of next-generation cyber-security solutions to meet HIPAA compliance standards. Mindleap also welcomes its new Director of Program Management, Dyson Walker, who will support Mindleap in improving its platform and meeting and exceeding all relevant laws and regulations.HIPAA Compliance CertificationThe Health Insurance Portability and Accountability Act, also known as HIPAA, is US legislation that provides security provisions to safeguard medical information. The Mindleap software development and security team have undergone...

RESEARCH TRIANGLE PARK, N.C., Sept. 17, 2020 (GLOBE NEWSWIRE) — Liquidia Technologies, Inc. (NASDAQ: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products using its proprietary PRINT® technology, today announced that the special meeting of its stockholders to vote on the proposed acquisition of RareGen, LLC pursuant to the Agreement and Plan of Merger, dated June 29, 2020, will be held on October 21, 2020, at 4:30 p.m., Eastern Time. On September 16, 2020, Liquidia Corporation’s Registration Statement on Form S-4 relating to the proposed acquisition was declared effective by the U.S. Securities and Exchange Commission (the “SEC”).The special meeting of Liquidia Technologies stockholders to vote on certain matters related to the proposed acquisition will be held...